Skip to main content
Fig. 4 | Respiratory Research

Fig. 4

From: Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma

Fig. 4

The functional activity determination of the trivalent IL-5-HSA Nb. A The binding activity of the trivalent IL-5-HSA Nb towards human IL-5 and cyno IL-5. B The binding activity of the trivalent IL-5-HSA Nb towards HSA and CSA at pH 5.5 and pH 7.4. The binding activity was detected by ELISA. C The blocking effect of trivalent IL-5-HSA Nb or Nucala analogue on the IL-5/IL-5R interaction was determined by flow cytometry. D The inhibitory effect of trivalent IL-5-HSA Nb or Nucala analogue on TF-1-cell proliferation was determined by the CCK8 assay

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us